Jinyu Bio-technology (SHA:600201) said that its subsidiary, Liaoning Yikang Biotech, received approval from China's Ministry of Agriculture and Rural Affairs to produce Jinmiaole, according to a Monday filing with the Shanghai bourse.
Jinmiaole is a trivalent inactivated vaccine for feline panleukopenia, rhinotracheitis, and calicivirus (FP/15 strain + FH/AS strain + FC/HF strain).
The approval is valid from Jan. 2, 2025, to Jan. 1, 2027.